Trial Profile
Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 25 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology